Hasegawa and Nakayama proved through mouse experiments that the arthritis inflammation and airway inflammation in mice lacking the CD69 gene were significantly reduced, suggesting that this gene might become a new target for the treatment of arthritis and asthma [30]. This evidence concerns the gene CD69 and Arthritis.